

# CSL Research Acceleration Initiative

Applications close 12<sup>th</sup> March 2021

## WHY COLLABORATE WITH CSL?



**Global** Capabilities  
on your doorstep



**Work** with one of the  
world's leading biotech  
companies



**Funding** for successful  
proposals




**Access** to commercial  
R&D, clinical, intellectual  
property, marketing and  
manufacturing expertise



**Accelerate** translation  
of your research to deliver  
new therapies to patients

CSL's Research Acceleration Initiative aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organisations.

The 2021 Research Acceleration Initiative will focus on research proposals that align with a **CSL Therapeutic Area** and are amenable to or include a **Modality** as illustrated below. Please see over page for specific **Focus Areas**.



Successful applicants will receive up to USD 200k p.a. for up to 2 years (max USD 400k funding).

Researchers who wish to apply are required to submit a 300 word online pre-application by **12<sup>th</sup> March 2021** via the following link  
<https://servicesplatform.partneringplace.com/OppPortal/portal/csl/>.


Shortlisted applicants will then be invited to submit a detailed proposal in April.

Interested researchers are invited to join an online information session to learn more. Times and links will be announced separately by your Research or Innovation Office.  
*Please note: only Researchers from registered Institutions are eligible to apply*

# CSL Research Acceleration Initiative

## Focus Areas

CSL is seeking applications in the following **Focus Areas**:



Focus Areas	Autoimmune diseases	Sickle cell disease	Interstitial lung diseases (progressive, fibrosing)	Rare lipid disorders (e.g. Familial hypercholesterol-emia, Familial chylomicronemia)	Tolerance (Solid organ transplant/HSCT)
	Novel biologic targets/therapeutics or strategies to understand pathomechanisms of: Sjögren's syndrome, Systemic sclerosis, SLE, Pemphigus vulgaris, Hidradenitis suppurativa, Dermatomyositis, other rare rheumatological/dermatological conditions	Prophylactic therapies to reduce vaso-occlusive crises and chronic vasculopathy	Novel biologic targets/therapeutics	In vivo gene-editing and technologies for liver targeted delivery	Novel strategies or biologics to induce tolerance (T regs, T cell anergy and/or tolerogenic DCs)
	<b>Inflammation</b> Novel strategies to modulate the immune system to treat inflammatory diseases (including neuroinflammation e.g. CIDP)	<b>Ischemic and hemorrhagic stroke</b> Novel biologic targets/therapeutics or strategies to understand pathomechanisms	Biomarker/Omics approaches for patient stratification and drug discovery	<b>Severe forms of atherosclerosis</b> Novel biologic targets/therapeutics or strategies to understand pathomechanisms	<b>Graft vs host disease</b> Novel biologic targets/therapeutics to modulate the immune response for treatment and prevention
	<b>Next generation IVIG / alternatives to plasma-derived IVIG</b>	Focus on neuro- and thrombo-inflammation/ novel thrombolytics	Novel animal and human disease models	<b>Refractory angina</b> Novel biologic targets/therapeutics	<b>Acute rejection (Antibody-mediated rejection)</b> Novel biologic targets/therapeutics to modulate the immune response
		Biomarker/Omics approaches for patient stratification and drug discovery	<b>Acute respiratory distress syndrome</b> Novel biologic targets/therapeutics	<b>Myocarditis</b> Novel biologic targets/therapeutics	<b>Hematopoietic stem cell transplants</b> Strategies to improve efficacy/ safety, including inducing stem cell mobilisation, reducing toxicity of BM conditioning, improvement of engraftment
		<b>Hemophilia</b> In vivo gene-editing and technologies for liver targeted delivery	<b>Alpha-1 antitrypsin deficiency</b> In vivo gene-editing and technologies for liver targeted delivery	<b>Novel animal and human disease models</b>  Access to patient samples	

CSL is also interested in new uses for our existing products. If you have a proposal in this area, please e-mail [RAI@csl.com.au](mailto:RAI@csl.com.au) to discuss.